Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BBLG 
Bone Biologics Corp (BBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.5
1 Year Target Price $22.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.33% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.84M USD | Price to earnings Ratio - | 1Y Target Price 22.5 |
Price to earnings Ratio - | 1Y Target Price 22.5 | ||
Volume (30-day avg) 1 | Beta 1.3 | 52 Weeks Range 1.95 - 16.50 | Updated Date 09/17/2025 |
52 Weeks Range 1.95 - 16.50 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.63% | Return on Equity (TTM) -88.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2798612 | Price to Sales(TTM) - |
Enterprise Value -2798612 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 1795260 | Shares Floating 1638983 |
Shares Outstanding 1795260 | Shares Floating 1638983 | ||
Percent Insiders 8.31 | Percent Institutions 0.12 |
Upturn AI SWOT
Bone Biologics Corp
Company Overview
History and Background
Bone Biologics Corp was founded in 2004. The company focuses on bone regeneration technology. They have transitioned through various stages of development, research, and clinical trials, and have aimed to bring innovative solutions to the orthopedic market.
Core Business Areas
- OsteoMimetic Technology (OST):: Bone Biologics' core business is the development and commercialization of OST, a recombinant human protein that promotes bone regeneration. The initial target application is spinal fusion surgery.
Leadership and Structure
Dr. Robert Pyne is the CEO. The company has a board of directors overseeing strategic decisions. The organizational structure includes departments for research and development, clinical trials, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- NEMO Osteo-Protective Bone Putty: : NEMO is a bone graft substitute containing OST for use in bone regeneration. Market share data is difficult to pinpoint due to limited revenue. Competitors include Medtronic (MDT), Stryker (SYK), and NuVasive (NUVA) in the broader bone graft market.
- i-FACTOR Bone Graft: : i-FACTOR Peptide Enhanced Bone Graft is a bone graft using P-15 technology. Market share data is difficult to pinpoint due to limited revenue. Competitors include Medtronic (MDT), Stryker (SYK), and NuVasive (NUVA) in the broader bone graft market.
Market Dynamics
Industry Overview
The bone graft and biomaterials market is large and growing, driven by aging populations, increasing orthopedic surgeries, and advancements in regenerative medicine.
Positioning
Bone Biologics is a smaller player focused on a specific technology (OST). Competitive advantages may stem from unique efficacy of the OST protein in bone regeneration. They are positioning themselves as a technology innovator.
Total Addressable Market (TAM)
The global bone graft substitutes market is estimated at billions of dollars. Bone Biologics is aiming to capture a portion of this TAM with their OST technology. The degree to which they penetrate this market depends heavily on clinical outcomes, regulatory approvals, and commercialization strategies.
Upturn SWOT Analysis
Strengths
- Proprietary OST technology
- Potential for superior bone regeneration compared to existing grafts
- Focus on spinal fusion market
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Small market capitalization
- Minimal Revenue
Opportunities
- Partnerships with larger orthopedic companies
- Expansion into other bone regeneration applications (e.g., trauma)
- Positive clinical trial results
- Regulatory Approvals
Threats
- Competition from established players (Medtronic, Stryker, J&J)
- Unsuccessful clinical trials
- Regulatory hurdles
- Potential for new, competing technologies
Competitors and Market Share
Key Competitors
- MDT
- SYK
- NUVA
Competitive Landscape
Bone Biologics faces significant competition from established players. Their success depends on demonstrating superior efficacy with OST and securing partnerships to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to pre-revenue stage.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals for OST. Analyst projections will vary based on these factors.
Recent Initiatives: Recent initiatives likely focus on advancing clinical trials and seeking partnerships for commercialization.
Summary
Bone Biologics is a developmental-stage company with promising bone regeneration technology (OST). Its success hinges on the outcome of clinical trials and regulatory approvals. The company faces intense competition from larger, well-established players. Financial resources are limited, making partnerships crucial for commercialization. Investors should be aware of the high risks associated with this type of company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bone Biologics Corp
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2016-03-31 | CEO & President Mr. Jeffrey Frelick | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2 | Website https://www.bonebiologics.com |
Full time employees 2 | Website https://www.bonebiologics.com | ||
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.